MIRA INFORM REPORT

 

 

Report Date :

05.08.2013

 

IDENTIFICATION DETAILS

 

Name :

VIVATIS PHARMA GMBH

 

 

Registered Office :

Muhlendamm 66a Hamburg, 22087

 

 

Country :

Germany

 

 

Financials (as on) :

31.12.2011

 

 

Date of Incorporation :

08.02.2000

 

 

Com. Reg. No.:

HRB74650

 

 

Legal Form :

Private Independent

 

 

Line of Business :

Non-specialised wholesale trade

 

 

No. of Employees :

31

 

RATING & COMMENTS

 

MIRA’s Rating :

Ba

 

RATING

STATUS

PROPOSED CREDIT LINE

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

Satisfactory

 

Status :

Satisfactory

Payment Behaviour :

No Complaints

Litigation :

Clear

 

 

NOTES :

Any query related to this report can be made on e-mail: infodept@mirainform.com while quoting report number, name and date.

 

ECGC Country Risk Classification List – March 31st, 2013

 

Country Name

Previous Rating

(31.12.2012)

Current Rating

(31.03.2013)

Germany

A1

A1

 

Risk Category

ECGC Classification

Insignificant

 

A1

Low

 

A2

Moderate

 

B1

High

 

B2

Very High

 

C1

Restricted

 

C2

Off-credit

 

D

 

 

GERMANY - ECONOMIC OVERVIEW

 

The German economy - the fifth largest economy in the world in PPP terms and Europe's largest - is a leading exporter of machinery, vehicles, chemicals, and household equipment and benefits from a highly skilled labor force. Like its Western European neighbors, Germany faces significant demographic challenges to sustained long-term growth. Low fertility rates and declining net immigration are increasing pressure on the country's social welfare system and necessitate structural reforms. Reforms launched by the government of Chancellor Gerhard SCHROEDER (1998-2005), deemed necessary to address chronically high unemployment and low average growth, contributed to strong growth in 2006 and 2007 and falling unemployment. These advances, as well as a government subsidized, reduced working hour scheme, help explain the relatively modest increase in unemployment during the 2008-09 recession - the deepest since World War II - and its decrease to 6.5% in 2012. GDP contracted 5.1% in 2009 but grew by 4.2% in 2010, and 3.0% in 2011, before dipping to 0.7% in 2012 - a reflection of low investment spending due to crisis-induced uncertainty and the decreased demand for German exports from recession-stricken periphery countries. Stimulus and stabilization efforts initiated in 2008 and 2009 and tax cuts introduced in Chancellor Angela MERKEL's second term increased Germany's total budget deficit - including federal, state, and municipal - to 4.1% in 2010, but slower spending and higher tax revenues reduced the deficit to 0.8% in 2011. In 2012 Germany reached a budget surplus of 0.1%. A constitutional amendment approved in 2009 limits the federal government to structural deficits of no more than 0.35% of GDP per annum as of 2016 though the target was already reached in 2012. By 2014, the federal government wants to balance its budget. Following the March 2011 Fukushima nuclear disaster, Chancellor Angela Merkel announced in May 2011 that eight of the country's 17 nuclear reactors would be shut down immediately and the remaining plants would close by 2022. Germany hopes to replace nuclear power with renewable energy. Before the shutdown of the eight reactors, Germany relied on nuclear power for 23% of its electricity generating capacity and 46% of its base-load electricity production.

Source : CIA


 

Company name and address Top of Form

Bottom of Form

Top of Form

 

VIVATIS PHARMA GmbH

                                                                                                                                                   

 

Muhlendamm 66a

 

 

Hamburg, 22087

Germany

 

 

Tel:

+49 (0) 40 2369090

Fax:

+49 (0) 40 23690936

 

 

 

Employees:

31

Company Type:

Private Independent

 

 

Incorporation Date:

08-Feb-2000

Financials in:

 USD (mil)

Fiscal Year End:

31-Dec-2011

Reporting Currency:

Euro

Annual Sales:

NA

Total Assets:

13.9

                                      

Business Description       

 

VIVATIS PHARMA GmbH is primarily engaged in wholesale of furniture; wholesale of jewellery; wholesale of musical instruments; wholesale of photographic goods; wholesale of toys and games; wholesale of travel and fancy goods; and wholesale of other household goods not elsewhere classified.

          

Industry                                                                                                                                      

 

Industry

Miscellaneous Wholesale

ANZSIC 2006:

3739 - Other Goods Wholesaling Not Elsewhere Classified

ISIC Rev 4:

4690 - Non-specialized wholesale trade

NACE Rev 2:

4690 - Non-specialised wholesale trade

NAICS 2012:

423990 - Other Miscellaneous Durable Goods Merchant Wholesalers

UK SIC 2007:

4690 - Non-specialised wholesale trade

US SIC 1987:

5122 - Drugs, Drug Proprietaries, and Druggists' Sundries

                      

Key Executives           

   

 

Name

Title

Thomas Boner

Managing director

Peter Bos

Managing director

Peter Franck

Managing director

1 - Profit & Loss Item Exchange Rate: USD 1 = EUR 0.7191895
2 - Balance Sheet Item Exchange Rate: USD 1 = EUR 0.770327

 

 


Corporate Overview

 

Location
MĂ¼hlendamm 66a
Hamburg, 22087
Germany

 

Tel:

+49 (0) 40 2369090

Fax:

+49 (0) 40 23690936

 

Suggest Company URL

 

Sales EUR(mil):

NA

Assets EUR(mil):

10.7

Employees:

31

Fiscal Year End:

31-Dec-2011

 

Industry:

Miscellaneous Capital Goods

Incorporation Date:

08-Feb-2000

Company Type:

Private Independent

Quoted Status:

Not Quoted

Registered No.():

HRB74650

Parent Registered No.(UK):

DEU

 

Managing director:

Peter Bos

 

 

 

Industry Codes

 

ANZSIC 2006 Codes:

3739

-

Other Goods Wholesaling Not Elsewhere Classified

3720

-

Pharmaceutical and Toiletry Goods Wholesaling

 

ISIC Rev 4 Codes:

4690

-

Non-specialized wholesale trade

4649

-

Wholesale of other household goods

 

NACE Rev 2 Codes:

4690

-

Non-specialised wholesale trade

4645

-

Wholesale of perfume and cosmetics

 

NAICS 2012 Codes:

423990

-

Other Miscellaneous Durable Goods Merchant Wholesalers

424210

-

Drugs and Druggists' Sundries Merchant Wholesalers

 

US SIC 1987:

5122

-

Drugs, Drug Proprietaries, and Druggists' Sundries

 

UK SIC 2007:

4690

-

Non-specialised wholesale trade

4645

-

Wholesale of perfume and cosmetics

 

Business Description

VIVATIS PHARMA GmbH is primarily engaged in wholesale of furniture; wholesale of jewellery; wholesale of musical instruments; wholesale of photographic goods; wholesale of toys and games; wholesale of travel and fancy goods; and wholesale of other household goods not elsewhere classified.

 

 

 

 

 

 

Financial Data

Financials in:

EUR(mil)

 

Assets:

10.7

Current Assets:

10.6

 

Total Liabilities:

10.7

 

Issued Capital:

0.0

 

Net Worth:

4.1

 

 

 

Date of Financial Data:

31-Dec-2011

 

1 Year Growth

NA

 

Subsidiaries

Company

Percentage Owned

Country

Vivatis Arzneimittel GmbH

 

Germany

 

 

 

 

Key Corporate Relationships

Bank:

Hamburger Sparkasse

 

 

 

 

 

 

 

 

 

 

 

Executives Report

 

Executives

 

Name

Title

Function

Thomas Boner

 

Managing director

Managing Director

Peter Bos

 

Managing director

Managing Director

Peter Franck

 

Managing director

Managing Director

 

Annual Profit & Loss

 

 

 

31-Dec-2011

31-Dec-2010

31-Dec-2009

Period Length

12 Months

12 Months

12 Months

Filed Currency

EUR

EUR

EUR

Exchange Rate (Period Average)

0.71919

0.755078

0.719047

Consolidated

No

No

No

 

 

 

 

Taxes and social security costs

0.4

0.4

0.4

Total payroll costs

2.8

2.7

3.2

Fixed asset depreciation and amortisation

0.1

0.1

0.1

Other operating costs

1.9

1.8

2.8

Net operating income

1.4

1.3

3.4

Interest received from loans

1.1

0.9

-

Other income

0.0

0.0

0.0

Interest payable on loans

0.1

0.0

0.1

Total expenses

-1.0

-0.9

0.0

Profit before tax

2.4

2.2

3.3

Provisions

1.0

1.0

0.8

Extraordinary expenses

0.0

0.0

-

Extraordinary result

0.0

0.0

-

Other taxes

0.0

0.0

0.0

Total taxation

0.5

0.6

0.9

Net profit

2.0

1.6

2.4

 

 

 

Annual Balance Sheet

Financials in: USD (mil)

 

 

 

31-Dec-2011

31-Dec-2010

31-Dec-2009

Filed Currency

EUR

EUR

EUR

Exchange Rate

0.770327

0.745406

0.696986

Consolidated

No

No

No

 

 

 

 

Issued capital

0.0

0.0

0.0

Profits for the year

5.3

5.8

5.4

Total stockholders equity

5.4

5.9

5.4

Provisions and allowances

0.9

1.0

0.9

Total current liabilities

7.6

5.2

6.5

Total liabilities (including net worth)

13.9

12.1

12.8

Intangibles

0.0

0.0

0.0

Total tangible fixed assets

0.1

0.2

0.2

Shares held in associated companies

0.1

0.1

-

Total financial assets

0.1

0.1

-

Total non-current assets

0.2

0.3

0.2

Net stocks and work in progress

3.3

2.4

2.5

Total receivables

6.7

7.2

6.5

Cash and liquid assets

3.7

2.3

3.6

Total current assets

13.7

11.8

12.6

Prepaid expenses and deferred costs

0.0

0.0

0.0

Total assets

13.9

12.1

12.8

 

 

 

Annual Ratios

Financials in: USD (mil)

 

 

 

31-Dec-2011

31-Dec-2010

31-Dec-2009

Period Length

12 Months

12 Months

12 Months

Filed Currency

EUR

EUR

EUR

Exchange Rate

0.770327

0.745406

0.696986

Consolidated

No

No

No

 

 

 

 

Current ratio

18.01

22.58

19.19

Acid test ratio

13.66

18.09

15.40

Total liabilities to net worth

0.14%

0.09%

0.12%

Net worth to total assets

0.04%

0.05%

0.04%

Current liabilities to net worth

0.14%

0.09%

0.12%

Current liabilities to stock

0.23%

0.22%

0.26%

Fixed assets to net worth

0.00%

0.00%

0.00%

Return on assets

0.01%

0.01%

0.02%

Shareholders' return

0.03%

0.03%

0.05%

Profit per employee

4.58

3.91

4.30

Average wage per employee

6.58

6.47

5.77

Net worth

5.4

5.9

5.4

Number of employees

31

31

40

 

 

 

FOREIGN EXCHANGE RATES

 

Currency

Unit

Indian Rupees

US Dollar

1

Rs.60.80

UK Pound

1

Rs.91.95

Euro

1

Rs.80.36

 

 

INFORMATION DETAILS

 

Report Prepared by :

PRL

 

 

RATING EXPLANATIONS

 

RATING

STATUS

 

 

PROPOSED CREDIT LINE

>86

Aaa

Possesses an extremely sound financial base with the strongest capability for timely payment of interest and principal sums

 

Unlimited

71-85

Aa

Possesses adequate working capital. No caution needed for credit transaction. It has above average (strong) capability for payment of interest and principal sums

 

Large

56-70

A

Financial & operational base are regarded healthy. General unfavourable factors will not cause fatal effect. Satisfactory capability for payment of interest and principal sums

 

Fairly Large

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

 

Satisfactory

26-40

B

Capability to overcome financial difficulties seems comparatively below average.

 

Small

11-25

Ca

Adverse factors are apparent. Repayment of interest and principal sums in default or expected to be in default upon maturity

 

Limited with full security

<10

C

Absolute credit risk exists. Caution needed to be exercised

 

 

Credit not recommended

--

NB

New Business

 

--

 

This score serves as a reference to assess SC’s credit risk and to set the amount of credit to be extended. It is calculated from a composite of weighted scores obtained from each of the major sections of this report. The assessed factors and their relative weights (as indicated through %) are as follows:

 

Financial condition (40%)            Ownership background (20%)                 Payment record (10%)

Credit history (10%)                    Market trend (10%)                                Operational size (10%)

 

PRIVATE & CONFIDENTIAL : This information is provided to you at your request, you having employed MIPL for such purpose. You will use the information as aid only in determining the propriety of giving credit and generally as an aid to your business and for no other purpose. You will hold the information in strict confidence, and shall not reveal it or make it known to the subject persons, firms or corporations or to any other. MIPL does not warrant the correctness of the information as you hold it free of any liability whatsoever. You will be liable to and indemnify MIPL for any loss, damage or expense, occasioned by your breach or non observance of any one, or more of these conditions

This report is issued at your request without any risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL) or its officials.